Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis

Hospices Civils de Lyon600 enrolled

Overview

This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Paraneoplastic Neurological Syndrome Autoimmune Encephalitis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: \- Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018 Exclusion Criteria: * Data on location of diagnosis missing * Patients diagnosed out of the mainland French territory * Patients for whom insufficient data was available

Locations (1)

Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes

Lyon, France

Outcomes

Primary Outcomes

Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018.

Comparison between general population of the French counties and the cohort of PNS to calculate incidence and prevalence.

Time frame: 3 years

Secondary Outcomes

Location (city) of diagnosis

Name of city where the diagnosis of Paraneoplastic Neurological Syndromes (PNS) or Autoimmune Encephalitis (AE) was made.

Time frame: 1 hour

French general population of each counties

Person years for each region

Time frame: 3 years

Central Contacts

Géraldine Picard

CONTACT

4 72 35 58 42 geraldine.picard@chu-lyon.fr

Jérôme Honnorat

CONTACT

4 72 35 78 06 jerome.honnorat@chu-lyon.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.